Clinical Trial Update: BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B [Phase 1, Phase 2]

View source ↗

Summary

Be Biopharma's BE-101 is being studied in Phase 1/2 trials for adults with moderately severe to severe Hemophilia B, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BE-101

Snippet

Sponsor: Be Biopharma | Conditions: Hemophilia B, Hemophilia B, Moderately Severe or Severe | Phase 1, Phase 2 | Status: RECRUITING